Compass Pathways has submitted an FDA application for its synthetic psilocybin treatment for treatment-resistant depression, with a potential market launch in the first half of 2027 if approved. The submission comes two years after the FDA rejected an MDMA-assisted therapy for PTSD, a major setback for psychedelic treatments. The Trump administration has since taken steps to accelerate psychedelic research and patient access, and Compass was among three companies granted a faster FDA review process. Compass says the treatment could provide a new option for people with treatment-resistant depression who have not found meaningful relief from existing therapies.